Amgen Raises The Oncology Drug Price Bar With Blincyto
This article was originally published in The Pink Sheet Daily
Executive Summary
The first-in-class bispecific T-cell engager (BiTE) antibody will cost $178,000 for a median treatment regimen of two cycles, the company announced.
You may also be interested in...
Safety Profile Of Merck’s Anti-PD-1 Keytruda Shines In FDA Labeling
Priced at $12,500/month, Keytruda will be ready to ship within one week of FDA approval for relapsed melanoma after failure of Yervoy and a BRAF inhibitor. Approval could spur interest in off-label use of PD-1 inhibitor as a first-line treatment.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.